Thiol-based drugs are considered as mucolytics because they decrease the viscosity and mostly decrease the elasticity of bronchial secretions by reducing disulfide bonds in proteins. However, they can also act as antioxidant drugs directly through free sulfhydryl groups that serve as a source of reducing equivalents, as well as indirectly through the replenishment of intracellular glutathione (GSH) levels. Modulation of neurokinin A levels may also be related to the effect of thiol drugs on oxidative stress. Moreover, thiol-based drugs interfere with inflammatory pathways and modulate human bronchial tone. They might also be considered as therapeutic agents against some types of infection because they reduce bacterial adhesion to the respiratory epithelial cell surface and inhibit biofilm formation, causing biofilm disruption and thereby improving the efficacy of antibiotic therapy.

Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics / Cazzola, M.; Calzetta, L.; Page, C.; Rogliani, P.; Matera, M. G.. - In: TRENDS IN PHARMACOLOGICAL SCIENCES. - ISSN 0165-6147. - 40:7(2019), pp. 452-463. [10.1016/j.tips.2019.04.015]

Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics

Calzetta L.;
2019-01-01

Abstract

Thiol-based drugs are considered as mucolytics because they decrease the viscosity and mostly decrease the elasticity of bronchial secretions by reducing disulfide bonds in proteins. However, they can also act as antioxidant drugs directly through free sulfhydryl groups that serve as a source of reducing equivalents, as well as indirectly through the replenishment of intracellular glutathione (GSH) levels. Modulation of neurokinin A levels may also be related to the effect of thiol drugs on oxidative stress. Moreover, thiol-based drugs interfere with inflammatory pathways and modulate human bronchial tone. They might also be considered as therapeutic agents against some types of infection because they reduce bacterial adhesion to the respiratory epithelial cell surface and inhibit biofilm formation, causing biofilm disruption and thereby improving the efficacy of antibiotic therapy.
2019
Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics / Cazzola, M.; Calzetta, L.; Page, C.; Rogliani, P.; Matera, M. G.. - In: TRENDS IN PHARMACOLOGICAL SCIENCES. - ISSN 0165-6147. - 40:7(2019), pp. 452-463. [10.1016/j.tips.2019.04.015]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2910183
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 45
  • ???jsp.display-item.citation.isi??? 37
social impact